Precision BioSciences, Inc.
DTILHealthcareNASDAQBiotechnology
Scan Results
Daily timeframePrecision BioSciences, Inc., a clinical stage gene editing company, develops in vivo gene editing therapies for gene edits, including gene insertion, excision, and elimination in the United States. The company carries a $206.2M market cap, placing it firmly in the micro-cap category. The company offers ARCUS, a genome editing platform for DNA genome insertion, removal, and repair.
Market Cap
$206.2M
Beta
1.25
P/E (TTM)
—
P/E (Fwd)
-4.02
EPS (TTM)
$-1.32
EPS (Fwd)
$-1.86
ROE
-135.2%
ROA
-19.4%
Cash
$87.5M
Total Debt
$28.1M
Free CF
-$16.3M
52W Change
46.8%
Annual Financials
Cash vs Debt
Where DTIL stands vs its 150-day and 200-day moving averages
As of the September 3, 2026 close, DTIL finished 11.86% above its 150-day moving average ($6.66) and 21.34% above its 200-day moving average ($6.14). This snapshot is end-of-day data shown with a five-trading-day delay on the free plan; Premium members see readings from the latest close.
Is DTIL overbought or oversold?
At the September 3, 2026 close, DTIL's RSI(14) was 52.3, in neutral territory (between 30 and 70). The MACD histogram was negative, so short-term momentum leaned bearish at that close. These readings are historical, refresh daily after market close, and are not investment advice.
With $87.5M in cash and $28.1M in debt, DTIL maintains more liquidity than leverage. This favorable balance sheet position can be an asset when capital markets become less accommodating. The company is burning cash, with free cash flow at -$16.3M. This typically occurs when a company is investing aggressively in growth, but sustained cash burn can strain the balance sheet. Return on equity stands at -135.2%, which is negative for the sector. ROE measures how effectively a company uses shareholder capital to generate profits. Revenue has grown from $25.1M (2022) to $34.3M (2025), reflecting a 37% increase over the period.
The strong cash position relative to debt provides a financial cushion that reduces balance sheet risk. The company is burning cash at the operating level, which is not unusual for growth-phase companies but adds risk if it persists. No single metric tells the full story. Reviewing DTIL's risk profile alongside its fundamentals and technical indicators provides a more complete picture.